ArticleCell reports2015
ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis.
Article in Cell reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Identifying regulatory driver motifs in non-small cell lung carcinoma via a systematic approach.PloS one · 2026Pooled it
- Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Pooled it
- A canonical role of SMAD4 in safeguarding 3D genome architecture to suppress lung tumorigenesis.Oncogene · 2026Article
- A Non-Canonical Role of SMAD4 in Regulating 3D Genome Architecture to Inhibit Lung Squamous Cell Carcinoma Development.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Identification and characterization of a TGF-β-independent SMAD4-NFATc1-STAT3 regulatory axis.Journal of molecular cell biology · 2026Article
- Association of SMAD4 gene polymorphisms with human papillomavirus infection and risk of cervical cancer: a case-control study.BMC cancer · 2026Article
- MicroRNA-mediated changes contributing to benzo[a]pyrene toxicity in a 3D respiratory model for asthma.Current research in toxicology · 2026Article
- SMAD4-armed oncolytic adenovirus therapy potentiates the chemotherapy effects in NSCLC through suppression of the Wnt/β-catenin pathway.Cancer gene therapy · 2025Article
- The Associations of Air Pollution Mixture Exposure with Plasma Proteins in an Elderly U.S. Panel.Environmental science & technology · 2025Article
- EvaluatingTranslational cancer research · 2025Article
- MAGE-A4 induces non-small cell lung cancer and tumor-promoting plasma cell accumulation.Science advances · 2025Article
- Overexpression of ELF3 in the PTEN-deficient lung epithelium promotes lung cancer development by inhibiting ferroptosis.Cell death & disease · 2024Article
- TET2-STAT3-CXCL5 nexus promotes neutrophil lipid transfer to fuel lung adeno-to-squamous transition.The Journal of experimental medicine · 2024Article
- Screening of Immune-related lncRNAs in Lung Adenocarcinoma and Establishing a Survival Prognostic Risk Prediction Model.Combinatorial chemistry & high throughput screening · 2024Article
- The IL-17 family in diseases: from bench to bedside.Signal transduction and targeted therapy · 2023Review
- Shc3 facilitates breast cancer drug resistance by interacting with ErbB2 to initiate ErbB2/COX2/MDR1 axis.Cancer medicine · 2023Article
- Application status and future prospects of the PDX model in lung cancer.Frontiers in oncology · 2023Review
- Chronic exposure to carbon black ultrafine particles reprograms macrophage metabolism and accelerates lung cancer.Science advances · 2022Article
- Article
- Conditional ERK3 overexpression cooperates with PTEN deletion to promote lung adenocarcinoma formation in mice.Molecular oncology · 2022Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
Lung cancer remains the leading cause of cancer death. Genome sequencing of lung tumors from patients with squamous cell carcinoma has identified SMAD4 to be frequently mutated. Here, we use a mouse model to determine the molecular mechanisms by which Smad4 loss leads to lung cancer progression. Mice with ablation of Pten and Smad4 in airway epithelium develop metastatic adenosquamous tumors. Comparative transcriptomic and in vivo cistromic analyses determine that loss of PTEN and SMAD4 results in ELF3 and ErbB2 pathway activation due to decreased expression of ERRFI1, a negative regulator of ERBB2 in mouse and human cells. The combinatorial inhibition of ErbB2 and Akt signaling attenuate tumor progression and cell invasion, respectively. Expression profile analysis of human lung tumors substantiated the importance of the ErbB2/Akt/ELF3 signaling pathway as both a prognostic biomarker and a therapeutic drug target for treating lung cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.